CN108178790B - Method for separating cell membrane to screen transmembrane protein by using DNA coding compound library - Google Patents

Method for separating cell membrane to screen transmembrane protein by using DNA coding compound library Download PDF

Info

Publication number
CN108178790B
CN108178790B CN201810050638.4A CN201810050638A CN108178790B CN 108178790 B CN108178790 B CN 108178790B CN 201810050638 A CN201810050638 A CN 201810050638A CN 108178790 B CN108178790 B CN 108178790B
Authority
CN
China
Prior art keywords
screening
cell membrane
cells
dna
dna coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810050638.4A
Other languages
Chinese (zh)
Other versions
CN108178790A (en
Inventor
苏文姬
乐思远
陆恒
常伟
黄书宽
苗莹珂
李亚男
李颖洁
杨传秀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Apptec Co Ltd
Original Assignee
Wuxi Apptec Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Apptec Co Ltd filed Critical Wuxi Apptec Co Ltd
Priority to CN201810050638.4A priority Critical patent/CN108178790B/en
Publication of CN108178790A publication Critical patent/CN108178790A/en
Application granted granted Critical
Publication of CN108178790B publication Critical patent/CN108178790B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Abstract

The invention discloses a method for separating cell membranes so as to screen a transmembrane protein by a DNA coding compound library, which comprises the following steps: 1) physically disrupting the cells; 2) performing a first centrifugation cycle to separate soluble material and cell membranes and precipitate insoluble cellular structures; 3) carrying out high-speed centrifugation of a second round; 4) verifying the state of the separated cell membrane under a microscope; 5) and (3) screening a DNA coding compound library for transmembrane proteins by using cell membranes as carriers. The invention avoids the problem that the transmembrane protein loses the original structure in the purification process and simultaneously avoids the problem that the DNA coding compound library screened by living cells can not enter cells. Compared with the traditional high-throughput screening, the method improves the throughput of transmembrane protein drug screening, and simultaneously can improve the screening efficiency and reduce the screening cost.

Description

Method for separating cell membrane to screen transmembrane protein by using DNA coding compound library
Technical Field
The invention belongs to the field of drug screening, and particularly relates to a method for screening a DNA coding compound library, in particular to a method for separating cell membranes so as to screen a transmembrane protein through the DNA coding compound library.
Background
As a novel small molecule drug screening method, the DNA coding compound library can greatly improve the flux and speed of drug screening, reduce the cost of manpower and material resources and improve the screening efficiency. Transmembrane proteins are known to be difficult to purify and maintain the original structure, so that screening methods for transmembrane proteins using compounds encoded by DNA are very few, and the prior art has no method for comprehensively screening a library of compounds encoded by DNA while maintaining the structure of transmembrane proteins. At present, only one affinity screening method using living cells as carriers exists. The limitation of this approach is that DNA-encoded compounds, due to molecular size and charge, are directed only to the cell surface and do not efficiently cross the cell membrane into the cell interior, thus failing to screen for the intracellular region of the transmembrane protein. In addition, this method requires a high expression level of the protein, and consequently, the signal-to-noise ratio (signal-to-interference ratio) is low, and it is difficult to obtain effective data. Alternatively, transmembrane proteins are purified and screened, which results in proteins that have difficulty maintaining their structure and biological activity and low success rates for obtaining effective compounds.
Chinese patent application CN1646917A discloses a method for identifying compounds that interact with transmembrane proteins by separating cell membrane components to determine the level of transmembrane proteins containing nuclear localization sequences in the cell membrane and confirming the interaction of candidate compounds with transmembrane proteins by changes in the level of transmembrane proteins. The method is used as a verification mode for identifying whether the screened compound has an effect or not by aiming at the traditional high screening form, and cannot improve the screening flux and reduce the screening cost.
Therefore, there is a need to develop a method for screening a library of transmembrane proteins for DNA-encoded compounds that overcomes the above-mentioned deficiencies.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a method for separating cell membranes so as to screen a DNA coding compound library for transmembrane proteins, and in order to solve the problems in the prior art, the method utilizes a physical method to break cells and separate out cell membrane parts so as to keep the original structure of the proteins as much as possible, and is used for screening the DNA coding compound library so as to effectively screen drugs aiming at extracellular and intracellular regions of the transmembrane proteins.
In order to solve the technical problems, the invention adopts the technical scheme that:
a method of separating cell membranes for screening a library of transmembrane proteins for DNA-encoded compounds, comprising the steps of:
(1) physically disrupting the cells;
(2) performing a first centrifugation cycle to separate soluble material and cell membranes and precipitate insoluble cellular structures;
(3) performing a second round of high speed centrifugation to precipitate cell membranes from soluble cellular material;
(4) verifying the state of the separated cell membrane under a microscope;
(5) and (3) screening a DNA coding compound library for transmembrane proteins by using cell membranes as carriers.
As a preferred embodiment of the present invention, in step (1), the physical methods include homogenerizer (homogenizer, high speed stirrer), bead beater, and sonication (sonication).
As a preferable technical scheme of the invention, the following steps are added before the step (1): seeding the cells on a culture plate to grow a uniform monolayer of cells; cells were scraped into buffer with a spatula.
As a preferred embodiment of the present invention, the buffer solution comprises 20mM HEPES (hydroxyethylpiperazine ethanesulfonic acid), 250mM Sucrose, 10mM KCl, 2mM MgCl21mM EDTA (ethylenediaminetetraacetic acid), 1mM EGTA (ethylene glycol bis (2-aminoethylether) tetraacetic acid), 1mM DTT (dimercaptothreitol) and protease inhibitor cocktail (protease inhibitor cocktail) were added prior to use, pH 7.4.
As a preferred technical scheme of the invention, in the step (2), the first round of centrifugation is performed at the centrifugal force of 10,000g for 10 minutes at the temperature of 4 ℃.
In a preferred embodiment of the present invention, in step (3), the second round of high speed centrifugation is performed at a centrifugal force of 100,000g for 1 hour at a temperature of 4 ℃.
As a preferred technical scheme of the present invention, in the step (5), the screening process specifically comprises in sequence: cleaning, heating and high-speed centrifuging; in the screening process, high-speed centrifugation is used to separate soluble and cell membrane components so as to separate compounds which are not combined with protein; denaturing the protein by heating, allowing the bound compound to fall off the protein, into solution, and into the next round of screening; in total, one to three rounds of selection were performed until the total amount of extracted DNA-encoding compound was at 1X107To 1X109Within the range.
As a preferable technical scheme of the invention, in the step (5), the high-speed centrifugation is carried out, wherein the speed is 100,000g of centrifugal force, the time is 45 minutes, and the temperature is 4 ℃; the heating temperature is 80 ℃, and the heating time is 10 minutes.
As a preferable technical solution of the present invention, in the step (5), the cleaning specifically includes: adding the DNA coding compound library into a screening solution containing cell membranes, reacting, centrifuging, and washing with the screening solution; the screening medium consisted of 50mM Tris-HCl (Tris HCl), 150mM NaCl, 0.1% v/v Tween20 (Tween 20), 250mM Sucrose (Sucrose), 0.5mM EDTA, 1mM DTT (dimercaptothreitol), 1mg/mL fish sperm DNA (protamine DNA), 1mg/mL BSA (bovine serum albumin), pH 7.5.
As a preferable technical scheme of the invention, the following steps are added after the step (5):
(6) after a total of 1-3 rounds of screening of step (5), performing second-generation sequencing on the results to decode the structure of the compound;
(7) functional tests are carried out to verify the function of the compound.
Compared with the prior art, the invention has the beneficial effects that: the invention provides an effective screening method aiming at transmembrane proteins, which avoids the problem that the transmembrane proteins lose the original structure in the purification process and simultaneously avoids the problem that the DNA coding compound library screened by living cells cannot enter cells. The method can effectively apply the screening of the DNA coding compound library to the transmembrane protein target, the separated cell membrane is used for preparing the target protein before screening, the cell membrane is used as a carrier for fixing the target protein in the method to play a role, compared with the traditional high-throughput screening, the method improves the flux of screening transmembrane protein drugs, increases the flux from 1000 ten thousand compounds to more than 100 hundred million compounds, and can cover larger structural space. Meanwhile, the screening efficiency can be improved and reduced to 3-6 months from 9-18 months. The screening cost, including the cost of manpower and material, is reduced.
Drawings
The invention is further illustrated with reference to the following figures and examples.
FIG. 1 is a schematic flow diagram of the process of the present invention.
FIG. 2 is a graph showing the results of qPCR in example 1 of the present invention.
FIG. 3 is a graph showing the results of data analysis of the sequencing results in example 2 of the present invention.
FIG. 4 is a graphical representation of the IC50 results for Compound A of example 2 of the present invention.
Detailed Description
The present invention will now be described in further detail with reference to the accompanying drawings. These drawings are simplified schematic views illustrating only the basic structure of the present invention in a schematic manner, and thus show only the constitution related to the present invention.
Example 1: screening for positive compounds at the ETa receptor to confirm feasibility of the method
Firstly, background: ETa (receptor) belongs to GPCR, and is a protein with multiple transmembrane domains, which is difficult to purify while maintaining biological activity and structure
Secondly, the implementation method comprises the following steps:
as shown in fig. 1, the method specifically includes the following steps:
1. seeding cells expressing ETa receptor in T75 flasks to grow a uniform monolayer of cells;
2. cells were scraped into 3 ml of buffer with a spatula;
3. the buffer component was 20mM HEPES (hydroxyethylpiperazine ethanesulfonic acid), 250mM Sucrose, 10mM KCl, 2mM MgCl21mM EDTA (ethylene diamine tetraacetic acid), 1mM EGTA (ethylene glycol bis (2-aminoethylether) tetraacetic acid), 1mM DTT (dimercaptothreitol) and protease inhibitor cocktail (protease inhibitor cocktail) added prior to use, pH 7.4;
4. the cells were broken by back-and-forth aspiration 10 times with 5mL 27Gauge diameter needle tubing (Gauge is the unit of needle diameter);
5. the disrupted cells were placed on ice for 20 minutes;
6. a first centrifugation round was performed to separate out soluble material and cell membranes, precipitating insoluble cellular structures: centrifuging at 4 deg.C for 10 min with a centrifugal force of 10,000g to remove the pellet (containing nuclei, mitochondria) and retain the supernatant (containing cytoplasm and cell membrane);
7. transferring the supernatant to a new tube, and performing a second round of high speed centrifugation with a high speed centrifuge for 1 hr (centrifugal force of 100,000g, 4 deg.C), wherein the cell membrane is heavy and can be precipitated from soluble cell material;
8. the supernatant was removed and the pellet was washed through a 25 gauge diameter needle using 2 ml of buffer;
9. verifying the state of the separated cell membrane under a microscope; then centrifuging for 45 minutes again (100,000 g, 4 ℃), the cell membrane precipitated during the washing process is broken up, and the cell membrane needs to be centrifuged again to precipitate again;
10. removing the supernatant, and adding 3 ml of screening solution;
11. the screening medium consisted of 50mM Tris-HCl (Tris-HCl), 150mM NaCl, 0.1% v/v Tween20 (Tween 20), 250mM Sucrose (Sucrose), 0.5mM EDTA, 1mM DTT (dimercaptothreitol), 1mg/mL fish sperm DNA (protamine DNA;), 1mg/mL BSA (bovine serum albumin), pH 7.5;
12. adding about 1nmol of a DNA-encoding compound library (containing 50,000 compound structures) and 2pmol of a positive compound BQ-123 (enrichment degree of 100: 1) ligated with a DNA sequence to a cell membrane-containing screening solution;
13. reacting on a shaker at 4 ℃ overnight;
14. centrifugation for 45 minutes (100000 g of centrifugal force, 4 ℃);
15. removing the supernatant, washing the precipitate with 5ml of screening solution;
16. three washes in total, 10 minutes each, during which 45 minutes (100, 000g, 4 ℃) are centrifuged;
17. the remaining cell membranes were heated with 3 ml of the selection solution at 80 ℃ for 10 minutes;
18. centrifugation for 45 minutes (100000 g, 4 ℃);
19. the supernatant is reserved;
20. after each round of screening, approximately 20 μ L of supernatant was retained for qPCR to determine the enrichment of positive compound BQ-123;
21. one to three rounds of screening were performed until the enrichment degree of the positive compound BQ-123 reached 2000:1 or more;
22. the enrichment degree of the positive compound BQ-123 was determined by qPCR for the products after each round of screening. The qPCR results are schematically shown in figure 2. FIG. 2 shows the degree of enrichment of BQ-123 relative to compounds in the pool of other DNA-encoding compounds after two rounds of screening, 100:1 before screening, one round of screening increasing to 1000: 1, after two screening rounds, the ratio is increased to 2500:1, and the standard of more than 2000:1 is achieved, so that the screening is considered to be successful so far.
Example 2: screening of the V1a receptor for libraries of DNA-encoding compounds
Firstly, background: the V1a receptor belongs to GPCR, is a protein with multiple transmembrane domains, is difficult to purify and maintains biological activity and structure
Secondly, the implementation method comprises the following steps:
as shown in fig. 1, the method specifically includes the following steps:
1. growing a uniform monolayer of cells from cells expressing the V1a receptor on a 100mm plate;
2. scraping into 2 ml of buffer;
3. the buffer component was 20mM HEPES (hydroxyethylpiperazine ethanesulfonic acid), 250mM Sucrose, 10mM KCl, 2mM MgCl21mM EDTA (ethylene diamine tetraacetic acid), 1mM EGTA (ethylene glycol bis (2-aminoethylether) tetraacetic acid), 1mM DTT (dimercaptothreitol) and protease inhibitor cocktail (protease inhibitor cocktail) added prior to use, pH 7.4;
4. the cells were broken by back-and-forth aspiration 10 times with a 5mL 27gauge needle;
5. the disrupted cells were placed on ice for 20 minutes;
6. a first centrifugation round was performed to separate out soluble material and cell membranes, precipitating insoluble cellular structures: centrifuging at 4 deg.C for 10 min with a centrifugal force of 10000g to remove the precipitate (including nuclei, mitochondria) and retain the supernatant (including cytoplasm and cell membrane);
7. transferring the supernatant into a new tube, and performing a second round of high speed centrifugation with a high speed centrifuge for 1 hr (100000 g, 4 deg.C), wherein the cell membrane is heavy and can be precipitated from soluble cell material;
8. the supernatant was removed and the pellet was washed through a 25 gauge needle with 2 ml of buffer;
9. verifying the state of the separated cell membrane under a microscope; then centrifuging for 45 minutes again (100000 g, 4 ℃), wherein the cell membrane precipitated in the washing process is broken up and needs to be centrifuged again to precipitate again;
10. removing the supernatant, and adding 2 ml of screening solution;
11. the screening medium consisted of 50mM Tris-HCl (Tris-HCl), 150mM NaCl, 0.1% v/v Tween20 (Tween 20), 250mM Sucrose (Sucrose), 0.5mM EDTA, 1mM DTT (dimercaptothreitol), 1mg/mL fish sperm DNA (protamine DNA;), 1mg/mL BSA (bovine serum albumin), pH 7.5;
12. adding about 2.5nmol of a pool of DNA-encoding compounds to a cell membrane-containing selection solution;
13. reacting on a shaker at 4 ℃ overnight;
14. centrifugation for 45 minutes (100000 g, 4 ℃);
15. removing the supernatant, washing the precipitate with 5ml of screening solution;
16. three washes in total, 10 minutes each, during which 45 minutes of centrifugation (100000 g, 4 ℃) were performed;
17. the remaining cell membranes were heated with 2 ml of the selection solution at 80 ℃ for 10 minutes;
18. centrifugation for 45 minutes (100000 g, 4 ℃);
19. reserving the supernatant and carrying out the next round of screening;
20. one to three rounds of selection were performed until the total amount of extracted DNA encoding the compound was at 1X107To 1X109Within the range;
21. the final product is amplified by PCR and decoded by second-generation sequencing to obtain an effective compound structure A; the data analysis results of the sequencing results are schematically shown in FIG. 3. Each axis in FIG. 3 represents a DNA label, with three different DNA labels per compound. Each dot in the graph represents a compound screened out, and the size of the dot represents the degree of enrichment of the compound in the product. The most enriched compound structure (exemplified as compound a) was selected from figure 3 and synthesized separately.
22. And performing biological function verification on the compound A. Since V1a is a GPCR, FLIPR assay can be used to test the inhibitory effect of compounds on V1a activity. The IC50 results for compound a are shown schematically in figure 4. This figure shows that the inhibitory activity of the compound against the V1a receptor is 0.59 nmol.
The above is only a specific application example of the present invention, and the protection scope of the present invention is not limited in any way; other variations and modifications will be apparent to persons skilled in the art in light of the above description. All embodiments need not be described or illustrated herein. The technical solutions similar to the above embodiments formed by equivalent transformation or equivalent replacement fall within the scope of the claims of the present invention.

Claims (8)

1. A method of separating cell membranes for screening a library of transmembrane proteins for DNA encoding compounds, wherein the transmembrane protein is a GPCR receptor, comprising the steps of:
(1) physically disrupting the cells;
(2) performing a first centrifugation cycle to separate a supernatant containing soluble cellular material and precipitate insoluble cellular structures; the soluble cellular material comprises cell plasma and cell membrane; the insoluble cellular structure comprises a nucleus and mitochondria;
(3) performing a second round of high speed centrifugation to precipitate cell membranes from soluble cellular material;
(4) verifying the state of the separated cell membrane under a microscope;
(5) using cell membrane as carrier, screening transmembrane protein with DNA coding compound library, the screening process includes: adding the DNA coding compound library into a screening solution containing cell membranes, reacting, centrifuging at a high speed, removing supernatant, and washing the precipitate with the screening solution; heating the remaining cell membranes and the screening solution together; then high-speed centrifugation is carried out, supernatant is reserved, and the next round of screening is carried out; in the screening process, high-speed centrifugation is used for separating soluble components and cell membrane components so as to separate compounds which are not combined with the protein; denaturing the protein by heating, allowing the bound compound to fall off the protein, into solution, and into the next round of screening; a total of one to three rounds of selection were performed until the total amount of extracted DNA-encoding compounds was at 1X107To 1X109Within the range; in step (5), the composition of the screening solution was 50mM Tris-HCl, 150mM NaCl, 0.1% v/vTween20, 250mM sucrose, 0.5mM EDTA, 1mM DTT, 1mg/mL protamine DNA, 1mg/mL LBSA, pH 7.5.
2. The method of claim 1, wherein in step (1), the physical method comprises using a homogenizer, homogenizer or high speed stirrer, using a bead beater, or using sonication.
3. The method of claim 1, wherein the following steps are added before step (1): seeding the cells on a culture plate to grow a uniform monolayer of cells; cells were scraped into buffer with a spatula.
4. The method of claim 3, wherein the buffer composition is: 20mM HEPES, 250mM Sucrose, 10mM KCl, 2mM MgCl21mM EDTA, 1mM EGTA, 1mM DTT and protease inhibitor cocktail, pH 7.4, were added prior to use.
5. The method of claim 1, wherein in step (2), the first round of centrifugation is performed at a centrifugal force of 10,000g for 10 minutes at a temperature of 4 degrees celsius.
6. The method of claim 1, wherein in step (3), the second round of high speed centrifugation is performed at a centrifugal force of 100,000g for 1 hour at a temperature of 4 degrees celsius.
7. The method of claim 1, wherein in step (5), the high speed centrifugation is at a centrifugal force of 100,000g for 45 minutes at a temperature of 4 degrees Celsius; the heating temperature is 80 ℃, and the heating time is 10 minutes.
8. The method of claim 1, wherein the following steps are added after step (5):
(6) after a total of 1-3 rounds of screening of step (5), performing second-generation sequencing on the results to decode the structure of the compound;
(7) functional tests are carried out to verify the function of the compound.
CN201810050638.4A 2018-01-18 2018-01-18 Method for separating cell membrane to screen transmembrane protein by using DNA coding compound library Active CN108178790B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810050638.4A CN108178790B (en) 2018-01-18 2018-01-18 Method for separating cell membrane to screen transmembrane protein by using DNA coding compound library

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810050638.4A CN108178790B (en) 2018-01-18 2018-01-18 Method for separating cell membrane to screen transmembrane protein by using DNA coding compound library

Publications (2)

Publication Number Publication Date
CN108178790A CN108178790A (en) 2018-06-19
CN108178790B true CN108178790B (en) 2021-09-07

Family

ID=62551005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810050638.4A Active CN108178790B (en) 2018-01-18 2018-01-18 Method for separating cell membrane to screen transmembrane protein by using DNA coding compound library

Country Status (1)

Country Link
CN (1) CN108178790B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112430598A (en) * 2019-08-26 2021-03-02 成都先导药物开发股份有限公司 Method for screening living cell membrane protein of DNA coding compound library
CN110548304A (en) * 2019-09-07 2019-12-10 天津药明康德新药开发有限公司 centrifugal concentrator for removing boiling point solvent
CN111621463A (en) * 2020-06-02 2020-09-04 英文特生物技术(北京)有限公司 Method for separating total membrane from cells by column method
CN112210019A (en) * 2020-10-15 2021-01-12 广东省科学院生物工程研究所 Purification method of transmembrane region of membrane protein containing single transmembrane region

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646917A (en) * 2002-04-12 2005-07-27 布赖恩·F·奥当德 Method of identifying transmembrane protein-interacting compounds
CN101531997A (en) * 2008-03-13 2009-09-16 中国科学院上海生命科学研究院 Method and model for high throughout screening of G protein-coupled receptor ligand
CN104513313A (en) * 2013-09-27 2015-04-15 杭州鸿运华宁生物医药工程有限公司 Screening method of monoclonal antibody of transmembrane receptor
CN107130299A (en) * 2016-09-30 2017-09-05 深圳劲宇生物科技有限公司 A kind of DNA encoding library of molecules and method for screening compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232335A1 (en) * 2002-02-25 2003-12-18 Surber Mark W. Minicell-based screening for compounds and proteins that modulate the activity of signalling proteins
WO2009077173A2 (en) * 2007-12-19 2009-06-25 Philochem Ag Dna-encoded chemical libraries
CN104628810B (en) * 2013-11-08 2018-11-02 中国科学院大连化学物理研究所 A kind of cell membrane protein enrichment and purification method
CN106048736B (en) * 2015-04-14 2019-09-03 成都先导药物开发股份有限公司 A kind of method of synthesis in solid state DNA encoding compound library
EP3184674A1 (en) * 2015-12-23 2017-06-28 Technische Universität Dortmund Dna-encoded chemical library, use thereof and method to synthesize the library

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646917A (en) * 2002-04-12 2005-07-27 布赖恩·F·奥当德 Method of identifying transmembrane protein-interacting compounds
CN101531997A (en) * 2008-03-13 2009-09-16 中国科学院上海生命科学研究院 Method and model for high throughout screening of G protein-coupled receptor ligand
CN104513313A (en) * 2013-09-27 2015-04-15 杭州鸿运华宁生物医药工程有限公司 Screening method of monoclonal antibody of transmembrane receptor
CN107130299A (en) * 2016-09-30 2017-09-05 深圳劲宇生物科技有限公司 A kind of DNA encoding library of molecules and method for screening compound

Also Published As

Publication number Publication date
CN108178790A (en) 2018-06-19

Similar Documents

Publication Publication Date Title
CN108178790B (en) Method for separating cell membrane to screen transmembrane protein by using DNA coding compound library
US20230042817A1 (en) Analyte capture from an embedded biological sample
EP3027771B1 (en) Methods for the production of long length clonal sequence verified nucleic acid constructs
CN104350152B (en) Selective kernel acid fragment is reclaimed
Perez-Perri et al. Global analysis of RNA-binding protein dynamics by comparative and enhanced RNA interactome capture
CN109023535B (en) Method for screening DNA coding compound by using antibody to non-recognition marker protein or cell lysate
EP3794118A1 (en) In situ cell screening methods and systems
JP6556856B2 (en) Analytical method and analytical device
Mirzazadeh et al. Genome-wide profiling of DNA double-strand breaks by the BLESS and BLISS methods
CN108004246A (en) The method that liquid phase target SELEX screenings are quickly carried out using the affine method of metal
CN103975062B (en) Nucleic acid amplification method
US20240043919A1 (en) Method for traceable medium-throughput single-cell copy number sequencing
JP7049103B2 (en) Comprehensive 3'end gene expression analysis method for single cells
Antunes et al. Single-cell RNA sequencing and its applications in the study of psychiatric disorders
CN112111490B (en) Method for visualizing endogenous low-abundance single-molecule RNA in living cells and application
US20230151355A1 (en) Methods for Single Cell Intracellular Capture and its Applications
Goto et al. Excessive expression of the plant kinesin TBK5 converts cortical and perinuclear microtubules into a radial array emanating from a single focus
CN110564732B (en) Nucleic acid aptamer for detecting mouse mesenchymal stem cells and detection kit
TW201821609A (en) Cell scaffold material using e-cadherin-binding nucleic acid aptamer
WO2020092797A1 (en) Methods and uses of high-throughput inference of synaptic connectivity relationships among cell types
CN110564731B (en) Aptamer and detection kit for detecting human drug-resistant hepatoma cell strain HepG2/ADM
Fazal et al. APEX-seq: RNA subcellular localization by proximity labeling
CN113801915B (en) Method for obtaining target RNA of target RNA binding protein
JP2005336107A (en) Method for recovering nucleic acid in high efficiency
WO2024036284A1 (en) Generation and selection of affinity reagents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant